Investment
Features
FeesSafety
Academy
More
Pluang+

Xtant Medical to release Q4 and full-year 2025 financial results on March 31, 2026

Company Fundamentals
25 Mar 2026
PRNewsWire
View Source
Neutral
pluang ai news

Xtant Medical Holdings, a company specializing in surgical solutions for spinal and orthopedic conditions, announced it will release its financial results for the fourth quarter and full year ending December 31, 2025, on March 31, 2026, before market open. The company's CEO and CFO will host a conference call at 8:30 AM ET on the same day to discuss the results. Investors can access a live webcast and a replay will be available on Xtant Medical's website. This update provides insight into the company's recent financial performance and future outlook.

More News

Health plan cuts machine-readable file production from 45 days to under 24 hours with TALON integration

Health plan cuts machine-readable file production from 45 days to under 24 hours with TALON integration

A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...

Others
Neutral
1 hour ago
ASUS launches new durable Chromebooks CM15 and CM32 with long battery life and Google AI features in the US

ASUS launches new durable Chromebooks CM15 and CM32 with long battery life and Google AI features in the US

ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...

Others
Bullish
2 hours ago
Slate Medicines appoints Mark W. Hahn to board to boost migraine drug development.

Slate Medicines appoints Mark W. Hahn to board to boost migraine drug development.

Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...

Company Fundamentals
Bullish
3 hours ago
Klarna's growth driven by strong financing, low-cost funding, and expanding customer base despite market volatility risks.

Klarna's growth driven by strong financing, low-cost funding, and expanding customer base despite market volatility risks.

Klarna benefits from maturing financing cohorts, low-cost deposit funding, and prudent risk management, leading to increased transaction margins and net interest income. This supports their growth strategy, reflected in accelerating gross merchandise...

Analyst Insights
Bullish
4 hours ago
Low-cost processing could double gallium grades at G50's Golconda project, with gold and silver as co-products.

Low-cost processing could double gallium grades at G50's Golconda project, with gold and silver as co-products.

G50 Corp announced that Phase 2 metallurgical tests at its Golconda project in Arizona show low-cost processing could double gallium grades while also producing gold and silver. This breakthrough reduces risks in gallium extraction, a critical minera...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App